<p>Electromed, Inc.（纽约证券交易所代码：ELMD - 免费报告）- Roth Capital 的股票研究分析师在 11 月 12 日星期三向投资者发布的研究报告中下调了 Electromed 2026 年第二季度每股收益（EPS）预期。Roth Capital 分析师 K. Bauser 现在预计该公司本季度每股收益为 0.25 美元，低于之前的 0.27 美元。Roth Capital 对该股票给予 &#34;买入&#34; 评级，目标价为 36.00 美元。Roth Capital 还对 Electromed 2026 年第三季度的每股收益预期为 0.25 美元，2026 财年的每股收益预期为 1.05 美元，2027 财年的每股收益预期为 1.25 美元。</p>
<p>其他分析师最近也发布了关于该股票的研究报告。Lake Street Capital 于 8 月 27 日星期三开始覆盖 Electromed 的股票。他们给予该公司的 &#34;买入&#34; 评级和 36.00 美元的目标价。Loop Capital 在 8 月 27 日星期三的研究报告中对 Electromed 设置了 36.00 美元的目标价。最后，Zacks Research 在 10 月 27 日星期一的研究报告中将 Electromed 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。一位股票研究分析师给予该股票 &#34;强力买入&#34; 评级，两位给予 &#34;买入&#34; 评级，一位给予 &#34;持有&#34; 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;买入&#34;，平均目标价为 36.50 美元。</p>
<p><strong>阅读我们对 Electromed 的最新分析</strong></p>
<h2>Electromed 股价下跌 5.0%</h2>
<p>Electromed 股票在星期五交易中下跌 1.31 美元，报 25.04 美元。该公司交易了 7,093 股，低于其平均交易量 77,355 股。该公司的市值为 2.0974 亿美元，市盈率为 33.39，贝塔值为 0.40。该公司的 50 日移动平均线为 24.60 美元，200 日移动平均线为 21.98 美元。Electromed 的 52 周低点为 17.73 美元，52 周高点为 35.56 美元。</p>
<h2>内部交易活动</h2>
<p>在其他新闻中，董事 Andrew Summers 于 9 月 11 日星期四出售了 3,153 股该公司的股票。股票以平均价格 24.42 美元出售，总交易额为 76,996.26 美元。该交易已在与 SEC 的法律文件中披露，可以通过此链接访问。目前，内部人士持有该股票的 10.50%。</p>
<h2>机构投资者对 Electromed 的看法</h2>
<p>大型投资者最近增加或减少了对该公司的持股。Millennium Management LLC 在第一季度将其在 Electromed 的持股增加了 362.7%。Millennium Management LLC 现在拥有 194,519 股该公司的股票，价值 4,641,000 美元，此前在上个季度购买了额外的 152,480 股。Geode Capital Management LLC 在第二季度将其在 Electromed 的持股增加了 128.3%。Geode Capital Management LLC 现在拥有 155,540 股该公司的股票，价值 3,421,000 美元，此前在上个季度购买了额外的 87,401 股。Acadian Asset Management LLC 在第一季度将其在 Electromed 的持股增加了 25.2%。Acadian Asset Management LLC 现在拥有 267,975 股该公司的股票，价值 6,388,000 美元，此前在该期间购买了额外的 53,872 股。摩根大通在第二季度将其在 Electromed 的持股增加了 117.7%。摩根大通现在拥有 64,371 股该公司的股票，价值 1,416,000 美元，此前在上个季度收购了额外的 34,799 股。最后，Jane Street Group LLC 在第一季度将其在 Electromed 的持股增加了 136.3%。Jane Street Group LLC 现在拥有 56,263 股该公司的股票，价值 1,342,000 美元，此前在上个季度购买了额外的 32,456 股。对冲基金和其他机构投资者持有该公司 40.82% 的股票。</p>
<h2>关于 Electromed</h2>
<p>（获取免费报告）</p>
<p>Electromed, Inc 开发、制造、营销和销售气道清理治疗及相关产品，应用高频胸壁振荡（HFCWO）治疗，服务于美国及国际各年龄段的患者。该公司为肺功能受损的患者提供 SmartVest 气道清理系统，包括支气管扩张症和囊性纤维化患者，以及神经肌肉疾病患者，如脑瘫和肌萎缩侧索硬化症；SmartVest SQL 系统；SmartVest Clearway 系统，包括一个充气治疗服、一个可编程气脉冲发生器和一个专利单管，能够将气脉冲从发生器传递到服装上，以在胸壁上产生振荡压力；以及 SmartVest Connect，一种无线技术，允许医生与患者之间的数据连接，以跟踪治疗效果并协作治疗决策。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Electromed 更好</li>
<li>零售股票投资，解析</li>
<li>CRWD 股票在财报前达到关键拐点</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>Rigetti 的第三季度失利揭示量子资金和时机压力</li>
<li>大型股定义及如何投资</li>
<li>Monolithic Power 在 2025 年激增——是时候买入还是持有？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Electromed 吗？</h2>
<p>在你考虑 Electromed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Electromed 并不在名单上。</p>
<p>虽然 Electromed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ELMD

<p>Roth Capital 将 Electromed 2026 年第二季度每股收益预期从 0.27 美元下调至 0.25 美元，维持 “买入” 评级，目标价为 36 美元。其他分析师也对该股票给予积极评价，平均目标价为 36.50 美元。Electromed 的股票最近下跌了 5%，至 25.04 美元。机构投资者正在调整其持股，Millennium Management 和 Geode Capital 的持股显著增加。Electromed 开发用于肺部护理的气道清理治疗产品，包括 SmartVest 系统</p>

<p>Electromed, Inc. (NYSE:ELMD - Free Report) - Equities research analysts at Roth Capital lowered their Q2 2026 earnings per share (EPS) estimates for shares of Electromed in a research note issued to investors on Wednesday, November 12th. Roth Capital analyst K. Bauser now anticipates that the company will post earnings of $0.25 per share for the quarter, down from their prior estimate of $0.27. Roth Capital has a &#34;Buy&#34; rating and a $36.00 price objective on the stock. Roth Capital also issued estimates for Electromed's Q3 2026 earnings at $0.25 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.25 EPS.</p>
<div class="lb-trans"><p>Electromed, Inc.（纽约证券交易所代码：ELMD - 免费报告）- Roth Capital 的股票研究分析师在 11 月 12 日星期三向投资者发布的研究报告中下调了 Electromed 2026 年第二季度每股收益（EPS）预期。Roth Capital 分析师 K. Bauser 现在预计该公司本季度每股收益为 0.25 美元，低于之前的 0.27 美元。Roth Capital 对该股票给予 &#34;买入&#34; 评级，目标价为 36.00 美元。Roth Capital 还对 Electromed 2026 年第三季度的每股收益预期为 0.25 美元，2026 财年的每股收益预期为 1.05 美元，2027 财年的每股收益预期为 1.25 美元。</p>
</div><p>Other analysts also recently issued research reports about the stock. Lake Street Capital began coverage on shares of Electromed in a report on Wednesday, August 27th. They issued a &#34;buy&#34; rating and a $36.00 target price for the company. Loop Capital set a $36.00 price target on Electromed in a research report on Wednesday, August 27th. Finally, Zacks Research cut Electromed from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average price target of $36.50.</p>
<div class="lb-trans"><p>其他分析师最近也发布了关于该股票的研究报告。Lake Street Capital 于 8 月 27 日星期三开始覆盖 Electromed 的股票。他们给予该公司的 &#34;买入&#34; 评级和 36.00 美元的目标价。Loop Capital 在 8 月 27 日星期三的研究报告中对 Electromed 设置了 36.00 美元的目标价。最后，Zacks Research 在 10 月 27 日星期一的研究报告中将 Electromed 的评级从 &#34;强力买入&#34; 下调至 &#34;持有&#34;。一位股票研究分析师给予该股票 &#34;强力买入&#34; 评级，两位给予 &#34;买入&#34; 评级，一位给予 &#34;持有&#34; 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;买入&#34;，平均目标价为 36.50 美元。</p>
</div><p><strong>Read Our Latest Analysis on Electromed</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Electromed 的最新分析</strong></p>
</div><h2>Electromed Trading Down 5.0%</h2>
<div class="lb-trans"><h2>Electromed 股价下跌 5.0%</h2>
</div><p>Electromed stock traded down $1.31 during trading on Friday, hitting $25.04. 7,093 shares of the company were exchanged, compared to its average volume of 77,355. The company has a market capitalization of $209.74 million, a P/E ratio of 33.39 and a beta of 0.40. The business's 50 day moving average is $24.60 and its 200 day moving average is $21.98. Electromed has a 52 week low of $17.73 and a 52 week high of $35.56.</p>
<div class="lb-trans"><p>Electromed 股票在星期五交易中下跌 1.31 美元，报 25.04 美元。该公司交易了 7,093 股，低于其平均交易量 77,355 股。该公司的市值为 2.0974 亿美元，市盈率为 33.39，贝塔值为 0.40。该公司的 50 日移动平均线为 24.60 美元，200 日移动平均线为 21.98 美元。Electromed 的 52 周低点为 17.73 美元，52 周高点为 35.56 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, Director Andrew Summers sold 3,153 shares of the company's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $24.42, for a total transaction of $76,996.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.50% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Andrew Summers 于 9 月 11 日星期四出售了 3,153 股该公司的股票。股票以平均价格 24.42 美元出售，总交易额为 76,996.26 美元。该交易已在与 SEC 的法律文件中披露，可以通过此链接访问。目前，内部人士持有该股票的 10.50%。</p>
</div><h2>Institutional Investors Weigh In On Electromed</h2>
<div class="lb-trans"><h2>机构投资者对 Electromed 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Millennium Management LLC lifted its holdings in Electromed by 362.7% during the first quarter. Millennium Management LLC now owns 194,519 shares of the company's stock valued at $4,641,000 after purchasing an additional 152,480 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Electromed by 128.3% in the second quarter. Geode Capital Management LLC now owns 155,540 shares of the company's stock worth $3,421,000 after purchasing an additional 87,401 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Electromed by 25.2% in the 1st quarter. Acadian Asset Management LLC now owns 267,975 shares of the company's stock worth $6,388,000 after buying an additional 53,872 shares during the period. JPMorgan Chase &amp; Co. lifted its position in shares of Electromed by 117.7% during the second quarter. JPMorgan Chase &amp; Co. now owns 64,371 shares of the company's stock worth $1,416,000 after acquiring an additional 34,799 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of Electromed by 136.3% in the first quarter. Jane Street Group LLC now owns 56,263 shares of the company's stock valued at $1,342,000 after purchasing an additional 32,456 shares in the last quarter. Hedge funds and other institutional investors own 40.82% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。Millennium Management LLC 在第一季度将其在 Electromed 的持股增加了 362.7%。Millennium Management LLC 现在拥有 194,519 股该公司的股票，价值 4,641,000 美元，此前在上个季度购买了额外的 152,480 股。Geode Capital Management LLC 在第二季度将其在 Electromed 的持股增加了 128.3%。Geode Capital Management LLC 现在拥有 155,540 股该公司的股票，价值 3,421,000 美元，此前在上个季度购买了额外的 87,401 股。Acadian Asset Management LLC 在第一季度将其在 Electromed 的持股增加了 25.2%。Acadian Asset Management LLC 现在拥有 267,975 股该公司的股票，价值 6,388,000 美元，此前在该期间购买了额外的 53,872 股。摩根大通在第二季度将其在 Electromed 的持股增加了 117.7%。摩根大通现在拥有 64,371 股该公司的股票，价值 1,416,000 美元，此前在上个季度收购了额外的 34,799 股。最后，Jane Street Group LLC 在第一季度将其在 Electromed 的持股增加了 136.3%。Jane Street Group LLC 现在拥有 56,263 股该公司的股票，价值 1,342,000 美元，此前在上个季度购买了额外的 32,456 股。对冲基金和其他机构投资者持有该公司 40.82% 的股票。</p>
</div><h2>About Electromed</h2>
<div class="lb-trans"><h2>关于 Electromed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.</p>
<div class="lb-trans"><p>Electromed, Inc 开发、制造、营销和销售气道清理治疗及相关产品，应用高频胸壁振荡（HFCWO）治疗，服务于美国及国际各年龄段的患者。该公司为肺功能受损的患者提供 SmartVest 气道清理系统，包括支气管扩张症和囊性纤维化患者，以及神经肌肉疾病患者，如脑瘫和肌萎缩侧索硬化症；SmartVest SQL 系统；SmartVest Clearway 系统，包括一个充气治疗服、一个可编程气脉冲发生器和一个专利单管，能够将气脉冲从发生器传递到服装上，以在胸壁上产生振荡压力；以及 SmartVest Connect，一种无线技术，允许医生与患者之间的数据连接，以跟踪治疗效果并协作治疗决策。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Electromed</li>
<li>Retail Stocks Investing, Explained</li>
<li>CRWD Stock Hits Key Inflection Point Ahead of Earnings</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Rigetti’s Q3 Miss Reveals Quantum Funding and Timing Pressures</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Monolithic Power Surges in 2025—Time to Buy or Hold?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Electromed 更好</li>
<li>零售股票投资，解析</li>
<li>CRWD 股票在财报前达到关键拐点</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>Rigetti 的第三季度失利揭示量子资金和时机压力</li>
<li>大型股定义及如何投资</li>
<li>Monolithic Power 在 2025 年激增——是时候买入还是持有？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVMTUQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=ELMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Electromed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Electromed 吗？</h2>
</div><p>Before you consider Electromed, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Electromed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Electromed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Electromed 并不在名单上。</p>
</div><p>While Electromed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Electromed 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Roth Capital 对 Electromed 第二季度的收益持负面展望